Memantine in Moderate-to-Severe Alzheimer's Disease

Abstract

Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.